Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 20, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Editor's Note: The "Qiming Weekly" column is published regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
In the wave of technology and innovation, every step entrepreneurs take deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and we invite you to join us in following the milestone moments of our portfolio companies.
Major Partnerships
01/
Unisound Partners with Nanning Rail To Upgrade Property Services Platform with Smart Convenience Features
Recently, the "Railway · Smart Life" mini-program — the integrated property services platform under Guangxi Nanning Rail Smart Living Service Group Co., Ltd. ("Nanning Rail") — was significantly upgraded with deep empowerment from Unisound's Beast Tooth Agent Platform and AI technology, a Qiming Venture Partners portfolio company. The upgrade focuses on two voice-interaction scenarios: maintenance reporting and AI-powered food ordering, precisely addressing pain points in community governance such as elderly users' difficulty with digital interfaces and slow property management response times. Through a full-chain model of "voice recognition + intelligent dispatching + convenient services," the platform redefines the paradigm of "efficient, intelligent, and warm" smart living, becoming residents' "24/7 online smart living assistant."
The realization of maintenance reporting and AI food ordering capabilities owes much to the exceptional capabilities of Unisound's Beast Tooth Agent Platform. The platform integrates multiple technologies including speech recognition, natural language processing, and machine learning to achieve multimodal voice-and-text interaction, precisely capturing "the urgency in repair requests" and "personalized preferences during food ordering." It also features low-code rapid deployment through a visual workflow engine, enabling adaptation to different community business processes without complex programming. Going forward, it can be quickly extended to scenarios such as security monitoring and government services. Additionally, the platform employs HTML5 responsive design compatible with multiple devices, with data encryption meeting national standards, ensuring reliable and trustworthy smart services.
02/
AMD and XSKY Reach Strategic Ecosystem Partnership
At the AMD Industry Ecosystem Partner Summit, XSKY — a Qiming Venture Partners portfolio company and AMD strategic partner — made a major appearance showcasing its full-chain collaborative achievements. CEO Xin Xu delivered a keynote speech titled "Reconstructing Data Value Through Hardware-Software Synergy," officially releasing distributed storage solutions and integrated appliance products based on AMD EPYC, and jointly launching a strategic cooperation ceremony with AMD and other partners. This industry gathering, combining technology insights, product launches, and ecosystem building, marks the formal beginning of deep collaboration between the two parties in technological innovation and market expansion.
The strategic partnership between XSKY and AMD stems from a deep shared conviction that "data defines the future." As a global semiconductor leader, AMD brings powerful hardware innovation capabilities to the data storage field, including high-performance EPYC processors and Pensando DPUs. XSKY, as a pioneer in software-defined storage, provides efficient support for data flow through its innovative technical architecture and intelligent scheduling capabilities. Their collaboration represents not only technical complementarity but also a high degree of mutual recognition of each other's innovation philosophies. Built on "complementary technology DNA," the two parties are constructing a symbiotic system of "hardware innovation + software definition."
03/
Superhexa Formally Signs Strategic Cooperation Agreement with Shangpin Eyewear
Recently, Superhexa — a Qiming Venture Partners portfolio company — formally signed a strategic cooperation agreement with Shangpin Eyewear, authorizing it as the exclusive distributor for Jiehuan AI Audio Glasses in Hebei Province. The two parties will engage in deep collaboration around product promotion, in-store experience, and standardized operations, jointly driving the adoption and localization of AI smart glasses in regional markets.
As a pioneering brand in China's AI smart glasses space, Superhexa consistently adheres to the product philosophy of "first make a good pair of glasses, then make a good pair of smart glasses." Its "Jiehuan AI Audio Glasses" achieve deep integration of eyewear and headphone functionality, featuring open sound field design, 48 hours of combined battery life, an ultralight 30.7-gram frame, and abundant frame styles with quick-swap design — balancing comfortable wear, fashionable styling, and intelligent interaction. The product has been connected to more than 10 mainstream AI large model platforms, supporting AI notification broadcasting, voice assistant, and face-to-face translation functions, widely applicable in high-frequency life scenarios such as commuting, office work, and travel — truly achieving "wearable and usable."
04/
Shangyue Technology Announces Winning Bid for Pengfei Group Enterprise Procurement Management System Project
Recently, Shangyue Technology — a Qiming Venture Partners portfolio company — announced that it has won the bid for Pengfei Group's enterprise procurement management system project. The two parties will jointly build an intelligent procurement management platform aligned with Pengfei Group's development needs.
Shangyue Technology will rely on its leading intelligent procurement solutions, cutting-edge product capabilities, professional services, and extensive practical experience to comprehensively and multi-dimensionally ensure the successful implementation of Pengfei Group's procurement management platform, contributing to Pengfei Group's construction of a green, low-carbon, high-quality development innovation demonstration zone.
05/
DeepWise Bohr Research Space Station Becomes Official Partner for Australia and Georgia International AI Olympiad
Recently, the Bohr Research Space Station under DeepWise — a Qiming Venture Partners portfolio company — formally became the official competition platform for the International Olympiad in Artificial Intelligence (IOAI) selection competitions in Australia and Georgia.
Both the Australian and Georgian IOAI selection competitions have partnered with the Bohr Research Space Station, which provides the competition problems. DeepWise's cross-border cooperation with IOAI represents not only a fusion of technology and education but also a microcosm of the transformation in global research paradigms. Through the Bohr Research Space Station, DeepWise is translating "AI for Science" from concept into accessible tools, enabling more young people and researchers to share in the scientific dividends of the intelligent era.
06/
Concord Pharmaceutical Group and DeepWise Sign Strategic Cooperation Framework Agreement
Recently, Concord Pharmaceutical Group and DeepWise — a Qiming Venture Partners portfolio company — reached cooperation on innovative targets and drug discovery in the nephrology field, jointly enhancing drug R&D efficiency.
Weijie Sun, founder and CEO of DeepWise, said: "As a listed pharmaceutical company, Concord Pharmaceutical Group has built deep expertise in nephrology, medical imaging, and women's and children's health, and has demonstrated tremendous innovative drive and execution in new drug R&D and the adoption of new technologies. This aligns perfectly with DeepWise's mission of advancing 'AI for Science.' We are honored to partner with Concord Pharmaceutical Group, leveraging DeepWise's core technological strengths in AI for Science platforms, AI-driven drug discovery, intelligent laboratories, and modernization of traditional Chinese medicine. I believe that through ecosystem co-creation, complementary advantages, and collaborative innovation, we will establish a model for AI-powered drug R&D and industrial quality improvement, addressing more unmet clinical needs."
07/
Shenzhen Hongji Medical Partners with Beijing Tsinghua Chang Gung Hospital to Co-Build Urology International Academy
At the 11th Tsinghua Urolithiasis Forum and the 2nd Tsinghua Urological Minimally Invasive Innovation Techniques Training Course, Beijing Tsinghua Chang Gung Hospital and Qiming Venture Partners portfolio company Shenzhen Hongji Medical jointly unveiled the "Tsinghua Chang Gung Hongji Medical Urology International Academy."
This marks a new phase in the medical-engineering collaboration between Shenzhen Hongji Medical and the Urology Department of Tsinghua Chang Gung Hospital. Shenzhen Hongji Medical will continue to contribute to deepening exchanges between China and international urology communities.
R&D Progress
01/
Abbisko Therapeutics' New Drug Application for Pimicotinib in Tenosynovial Giant Cell Tumor Accepted by National Medical Products Administration
Recently, Qiming Venture Partners portfolio company Abbisko Therapeutics (02256.HK) announced that the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for pimicotinib, a self-developed highly selective small-molecule CSF-1R inhibitor, as a Class 1 innovative drug for the treatment of adult patients with tenosynovial giant cell tumor (TGCT).
Pimicotinib is the first project developed independently by Abbisko Therapeutics to enter the NDA review process. Given its demonstrated outstanding clinical efficacy, safety, and tolerability across multiple clinical trials, it has the potential to provide a best-in-class treatment option for patients.
Dr. Yaochang Xu, Chairman and CEO of Abbisko Therapeutics, said: "The NDA filing for pimicotinib is a major milestone in Abbisko's development journey. With its excellent clinical efficacy and safety profile, pimicotinib will bring breakthrough treatment options to clinicians and patients, further strengthening our capabilities and resolve in innovative drug R&D."
02/
Zai Lab Presents Global Phase 1a/1b Clinical Data for ZL-1310 at American Society of Clinical Oncology Annual Meeting
Recently, Qiming Venture Partners portfolio company Zai Lab (NASDAQ:ZLAB, 09688.HK) announced that updated data from its ongoing global Phase 1a/1b clinical study (NCT06179069) were presented in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
The study evaluated zocilurtatug pelitecan (ZL-1310), Zai Lab's potential first-in-class Delta-like ligand (DLL3) antibody-drug conjugate (ADC), in patients with extensive-stage small cell lung cancer (ES-SCLC). The presented data included updated results from the dose-escalation portion, as well as first-reported dose-expansion data from a total of 89 enrolled patients across six dose cohorts.
Dr. Rafael G. Amado, President and Global Head of R&D at Zai Lab, said: "The continued safety and efficacy data for ZL-1310 highlight its significant opportunity to improve outcomes for patients with extensive-stage small cell lung cancer, and reinforce its potential to become a first-in-class DLL3-targeting ADC in this setting. We are advancing a clear strategy to expand ZL-1310 across multiple high-need DLL3-expressing solid tumors, and plan to submit our first marketing authorization application as early as next year."
03/
Insilico Medicine and Partner Discover Potent WDR5-MYC Interaction Inhibitor
Recently, Qiming Venture Partners portfolio company Insilico Medicine and research partner Huadong Medicine announced that, using Insilico Medicine's innovative generative AI technology and physics-based molecular modeling modules, they successfully discovered novel small-molecule inhibitors potently targeting the WD repeat-containing protein 5 (WDR5)-MYC protein-protein interaction. The research was published in Chemical Biology & Drug Design.
In this study, the team first used the generative AI-driven Chemistry42 platform to generate small-molecule inhibitors targeting WDR5, then applied ligand-based molecular generation technology incorporating anchor information to preserve key pharmacophores, ultimately discovering compound 8 (IC50=16.35μM) and compound 9 (IC50=1.91μM). Both compounds showed significantly improved inhibitory activity compared to the reference compound (IC50=20.86μM). Next, with support from AlChemistry, Chemistry42's physics-based tool, the team further optimized existing hit compounds. Notably, one lead compound named 9c-1 achieved a 35-fold improvement in activity compared to compound 3, reaching sub-micromolar binding affinity. This molecule represents a major advance and was identified as a potential candidate for potent WDR5-MYC protein-protein interaction (PPI) inhibitor therapy.
04/
Nature Medicine Publishes Phase 2a Clinical Study Results for Insilico Medicine's AI-Driven Anti-IPF Candidate Drug
Recently, the industry's first clinical proof-of-concept result for AI-driven drug R&D was published in Nature Medicine. Qiming Venture Partners portfolio company Insilico Medicine and its co-authors released safety and efficacy data from the Phase 2a clinical trial of TNIK inhibitor rentosertib (ISM001-055).
Rentosertib is a potential first-in-class small-molecule drug for the treatment of idiopathic pulmonary fibrosis (IPF), discovered and designed through Insilico Medicine's generative AI platform Pharma.AI. Additionally, exploratory biomarker analyses in the study further validated the biological mechanism of the novel target TNIK, discovered through AI methods, with results supporting rentosertib's potential anti-fibrotic and anti-inflammatory effects.
05/
Bioray Laboratories Announces Latest Clinical Data for RD06-03 in Relapsed or Refractory Acute B-Lymphoblastic Leukemia
Recently, Qiming Venture Partners portfolio company Bioray Laboratories presented the latest clinical data for its CD19-targeting universal CAR-T cell product RD06-03 in patients with relapsed or refractory acute B-lymphoblastic leukemia (R/R B-ALL) in an academic poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Overall, RD06-03 was well tolerated in R/R B-ALL patients. Under standard lymphodepletion regimens, significant expansion and high response rates were achieved at relatively low dose levels. Additionally, as an "off-the-shelf" universal CAR-T cell product with no HLA matching requirements, RD06-03 maintained favorable in vivo persistence characteristics — CAR-T cells remained detectable in 50% of patients at day 30, with the longest persistence exceeding three months. TCR/HLA gene editing and the ANSWER® platform significantly enhanced RD06-03's anti-rejection capabilities, representing meaningful progress in universal CAR-T cell therapy research.
06/
InferVision's AI-Powered Virtual Thin-Slice CT Research Published in Nature Portfolio Journal
Recently, Qiming Venture Partners portfolio company InferVision collaborated with leading research institutions across China and the US — including University of California, Los Angeles, Northeastern University, China-Japan Friendship Hospital, the First Medical Center of Chinese PLA General Hospital (301 Hospital), and Beijing Haidian Hospital — to publish a major research finding: using AI models to "upgrade" clinically common thick-slice CT scans into virtual thin-slice CT, significantly improving image quality and diagnostic performance. The results were formally published in npj Digital Medicine, a Nature Portfolio journal and JCR Q1 / Chinese Academy of Sciences Q1 TOP-tier publication.
InferVision led the core AI model development and deployment for this study. During the subjective evaluation phase, InferVision's research platform InferScholar supported experts in conducting qualitative assessments of image quality. During diagnostic validation, InferVision's flagship products InferRead CT Lung and InferRead CT Pneumonia were used for actual performance testing. This closed-loop research approach ensures that AI algorithms are derived from clinical data and that technical achievements translate into clinical applications.
Product Launches
01/
Zhipu AI Launches CoCo, First Enterprise Autonomous Agent with Memory
Building on its previously announced Agentic GLM strategy, Qiming Venture Partners portfolio company Zhipu AI has launched CoCo, the first enterprise autonomous agent with memory.
CoCo features three enterprise-grade capabilities: full-process work assistance with a deliverable-oriented approach that lets results speak for themselves; a memory mechanism that proactively serves each employee based on their role and needs; and deep integration with existing enterprise data resources and system tools to become an agent that truly understands the organization. Across government and enterprise scenarios, CoCo targets deliverable outcomes, empowering every workflow and helping every employee improve efficiency.
02/
Gan & Lee Pharmaceuticals' Insulin Aspart Formulation Approved in Malaysia
Recently, Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) announced that its insulin aspart formulation, commercialized in partnership with a local Malaysian pharmaceutical company, has received registration approval from Malaysia's National Pharmaceutical Regulatory Agency.
This rapid-acting insulin — insulin aspart — follows Gan & Lee's basal insulin (insulin glargine) approval in February and premixed insulin (insulin aspart 30) approval in March of this year in Malaysia, marking another successful insulin product approval for the company. This represents Gan & Lee's first achievement of full-series coverage across basal, rapid-acting, and premixed insulin formulations in a member country of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), a high-standard international GMP regulatory cooperation organization, bringing more quality treatment options to patients initiating or intensifying insulin therapy.
Rendu Biotechnology's Hepatitis B Virus Nucleic Acid Assay Kit (DNA Capture Probe Method) Approved in China
Recently, Qiming Venture Partners portfolio company Rendu Biotechnology (688193.SH) received approval from China's National Medical Products Administration (approval no. 国械注准20253401041) for its "Hepatitis B Virus Nucleic Acid Assay Kit (DNA Capture Probe Method)."
This assay is used for quantitative detection of hepatitis B virus DNA (HBV DNA) in human serum samples, a critical indicator for initiating antiviral therapy and assessing treatment efficacy. Combined with the company's existing HBV RNA detection, it forms a "dual-dimensional" testing approach — a powerful combination ushering in a new era of precision diagnosis and treatment for chronic hepatitis B.
Bioscience Anti-Müllerian Hormone (AMH) Assay Kit Formally Approved in China
Recently, Qiming Venture Partners portfolio company Bioscience announced that its anti-Müllerian hormone (AMH) assay kit (magnetic particle chemiluminescence method) has received formal approval in China.
Anti-Müllerian hormone is a key indicator for assessing ovarian reserve function in women, reflecting follicle inventory levels. Secreted by granulosa cells of small antral follicles (2-6mm) in the ovaries, AMH peaks during puberty and gradually declines with age, becoming virtually undetectable after menopause. This product is designed to evaluate ovarian reserve function and assist in diagnosing premature ovarian failure (POF); assist in diagnosing polycystic ovary syndrome (PCOS) and predicting menopause; evaluate disorders of sex development (DSD); and support ovarian tumor diagnosis.
Technology & Capabilities
WeRide Partners Again with Renault Group to Provide Autonomous Shuttle Service for French Open
Recently, Qiming Venture Partners portfolio company WeRide (NASDAQ: WRD) announced its renewed partnership with French Open premium partner Renault Group to provide the only on-site L4 autonomous shuttle service for the 2025 French Open — the world's premier clay-court Grand Slam tournament.
During last year's French Open shuttle service, WeRide's autonomous minibuses demonstrated sufficient safety and reliability in real, busy urban traffic scenarios. It is precisely because of this performance that WeRide's minibuses have returned to Roland Garros this year (editor's note: tennis mecca, French Open venue, and 2024 Paris Olympics site), further strengthening the partnership with Renault Group.
Tony Han, WeRide's founder and CEO, stated: "We are delighted to return to Roland Garros with our long-term partner Renault Group, continuing our shared vision of commercializing autonomous mobility in Europe. The second consecutive year of WeRide minibus service not only further strengthens confidence in our technology but also demonstrates its real-world application maturity. Europe is a key market in our global strategic footprint. Currently, our autonomous driving products have obtained operating licenses in five countries including France, and have commenced scaled commercial operations. We are accelerating our expansion, committed to bringing safer, smarter, and greener mobility to more European cities."
Hesai Technology Announces JT Series Cumulative Deliveries Exceed 100,000 Units, Setting Global Speed Record
Recently, Qiming Venture Partners portfolio company Hesai Technology (NASDAQ: HSAI) announced that cumulative deliveries of its JT series have surpassed 100,000 units — achieved in under five months since the product's January launch, making it the fastest LiDAR product in the robotics sector to reach this milestone. This demonstrates not only the JT series' strong competitiveness, but also its reliability and mass delivery capabilities as a mature architecture product, driving volume through actual orders to break industry records.
In 2017, delivering 100 LiDAR units via manual production lines took a full month. Today, thanks to Hesai Technology's self-built automated production lines, the same quantity can be delivered in approximately 30 minutes. This efficient, scaled mass production was no accident — it is the result of Hesai Technology's years-long commitment to in-house chip R&D and self-built production lines, continuously fortifying its core competitive moat. In 2025, Hesai Technology's planned annual production capacity will exceed 2 million units, steadily advancing toward higher volume targets.
Yunji Technology Appears at Hotel Digitalization (Huiyi) Practice Base Unveiling Ceremony
At the unveiling ceremony for the Hotel Digitalization (Huiyi) Practice Base, hosted by Huiyi Technology and supported by Qiming Venture Partners portfolio company Yunji Technology, Yunji Technology shared its thinking and practice on how "AI + robotics" is reshaping service models.
Zhi Tao, founder, chairman, and president of Yunji Technology, stated that Yunji is working to enable robots in hotel environments to understand customer needs, break down those needs, and anticipate them — elevating demand density, response flexibility, and service quality. The goal is to upgrade from mechanical, reactive service responses to comprehensive, chain-like predictive service. Yunji Technology has been deeply cultivating the trillion-yuan hotel market, and has gradually extended its mature service model to medical institutions, office buildings, factories, residential communities, and other scenarios — particularly special areas where humans face risks. To enable robots to perform more and more complex operations, Yunji is progressively deconstructing human movements and behaviors, working toward building an action foundation model. Going forward, digitalization in the hotel industry will require collaborative efforts across stakeholders to build an intelligent agent ecosystem and provide integrated solutions.
HyperStrong Completes Energy Storage Project Delivery for StarCharge Supercharging Station
Recently, Qiming Venture Partners portfolio company HyperStrong (688411.SH) completed the energy storage project delivery for StarCharge's Beidi Road supercharging station in Shanghai, setting a new benchmark for charging station energy management through precise peak-valley arbitrage strategies and intelligent power support technology.
As a key smart energy project in Shanghai, this supercharging station serves over 1,000 EV charging sessions daily, facing two major challenges: high electricity prices during peak charging periods and transformer overload during peak demand. Drawing on its deep understanding of charging-storage scenarios, HyperStrong deployed liquid-cooled outdoor cabinet products to address these pain points for the supercharging station. The energy storage system achieves two full power charge-discharge cycles daily, storing electricity during off-peak hours and releasing it during peak hours to execute precise peak-valley arbitrage. By monitoring transformer power conditions, it automatically provides short-term power support, reducing transformer stress while ensuring stable operation of liquid-cooled supercharging equipment — preventing revenue losses from power derating during peak charging periods.
HyperStrong Announces Successful Commissioning of Yunnan New-Type Shared Energy Storage Project
Recently, Qiming Venture Partners portfolio company HyperStrong (688411.SH) successfully commissioned a 100MW/200MWh new-type shared energy storage project in Malipo County, Yunnan Province. The project innovatively adopted HyperStrong's grid-forming energy storage technology and a hybrid "LFP + vanadium redox flow" technical route, combining rapid response, efficient charge-discharge, and long-cycle stable operation — providing critical support for building an integrated "generation-grid-load-storage" new-type power system, and fully demonstrating HyperStrong's industry-leading capabilities in hybrid energy storage system applications.
HyperStrong has built a full-lifecycle closed-loop service system. During project preparation, the technical team conducted multiple rounds of in-depth requirements discussions to precisely customize product selection and technical route solutions balancing economic viability and reliability. During construction implementation, professional engineers were stationed on-site throughout, strictly advancing engineering work according to technical standards. During project completion, a dedicated commissioning team launched a 7×24-hour joint debugging effort, achieving outstanding delivery quality.
06/
52TOYS Brings Three Original Trendy IPs to 2025 TOY HEART EXPO
Recently, Qiming Venture Partners portfolio company 52TOYS brought three original trendy IPs to the 2025 TOY HEART EXPO. NOOK, CiCiLu, and Pouka Pouka attracted attendees' attention with their distinctive designs and rich product offerings.
Since 2019, 52TOYS has built a portfolio of 35 original IPs spanning trendy, cultural, and sci-fi categories. The company will continue rolling out new trendy IPs such as NINNIC and diverse designer toy products to meet varied consumer demands. Going forward, 52TOYS will continue enriching its original IP matrix, bringing consumers more surprises through innovative products and diversified experiences.
07/
Sinogen Pharma Facilitates Over $700 Million Overseas Licensing Deal Between Genrix Bio and Cullinan
Recently, Genrix Bio (688443.SH) announced an overseas licensing agreement with Nasdaq-listed Cullinan Therapeutics, Inc. (NASDAQ: CGEM; "Cullinan"), with Qiming Venture Partners incubated company Sinogen Pharma serving as Genrix Bio's transaction advisor.
Under the agreement, Cullinan will obtain global development, manufacturing, and commercialization rights outside Greater China (mainland China, Hong Kong, Macau, and Taiwan) for Genrix Bio's anti-BCMA×CD3 bispecific antibody — GR1803 injection (Velinotamig). Genrix Bio will retain development, manufacturing, and commercialization rights for GR1803 in mainland China, and will actively advance development of existing clinical indications and domestic market approval. Genrix Bio will receive a $20 million upfront payment, up to $692 million in potential milestone payments, and tiered royalties on net sales outside Greater China.
In this exclusive licensing transaction, Sinogen Pharma served as Genrix Bio's BD advisor, providing full-process business services including options for different partnership models with multiple overseas biopharma companies and investment institutions, helping Genrix Bio receive several investment agreements.
Since its founding, the Sinogen Pharma team has cumulatively evaluated over 300 projects, partnered with more than 20 domestic companies, and facilitated 3 completed transactions. Cooperation projects span small molecules, large molecules, ADCs, cell therapy, and technology platforms, with therapeutic areas including oncology, autoimmunity, metabolism, and central nervous system diseases.
08/
Pulisihua Appears at 2025 Nigeria Lagos Healthcare Exhibition
Recently, Qiming Venture Partners portfolio company Pulisihua, a leading Chinese molecular diagnostics company, appeared at the WHX Lagos & WHX Labs Lagos 2025 exhibition in Lagos, Nigeria.
Its tuberculosis molecular testing solution drew significant attention at the event. The solution is innovatively compatible with both sputum and tongue swab sample types, with tongue swab samples particularly suitable for children, elderly patients, and immunocompromised individuals who cannot produce sputum. Data presented at the 55th Union World Conference on Lung Health in 2024 showed that Pulisihua's tongue swab test significantly exceeded WHO performance requirements for non-sputum-based near-patient diagnostics in both sensitivity and specificity. In actual deployment, the solution demonstrated clear advantages over traditional centralized testing workflows in terms of turnaround time, positive detection rate, and overall cost, offering a viable path toward building more efficient and sustainable grassroots disease prevention systems.
09/
Antai Micro-precision Powers World's First
Precise Resection of 20cm Elbow Tumor
Recently, Qiming Venture Partners portfolio company Antai Micro-precision collaborated with Professor Zhang Yixin's team from the Department of Plastic and Reconstructive Surgery at Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, to successfully complete the world's first complex tumor resection and reconstruction surgery assisted by the "Kai" microsurgical robot.
Under the precise operation of Associate Chief Physician Feng Shaoqing, the 12-hour surgery was completed successfully. The surgical team utilized the domestically developed "Kai" microsurgical robot system to resect a 20cm × 20cm giant dermatofibrosarcoma protuberans from the left elbow of a 29-year-old female patient, while simultaneously completing a highly complex free anterolateral thigh (ALT) perforator flap microsurgical reconstruction.
This surgery marked China's first robot-assisted precise resection of a giant tumor combined with complex reconstruction. Its success not only demonstrates China's innovation capabilities in high-end medical equipment, but also sets a new technical benchmark for microsurgery worldwide.
10/
Zhidin Medical Showcases Full Product Lines
for Fundus and Dry Eye at 26th Retina China
At the 26th China Fundus Disease Forum & International Retina Symposium, Qiming Venture Partners portfolio company Zhidin Medical showcased its full product lineup including the Luminor-A80 and Luminor-D60/D60M OCT angiography systems, D600 dry eye diagnostic device, domestic meibomian gland thermal pulsation treatment device, and medical ultrasonic nebulizer.
Zhidin Medical's innovative imaging technology and precise clinical application value received unanimous high praise from leading experts in attendance. Going forward, Zhidin Medical will remain unwavering in using scientific research and innovation as its engine to drive continuous iteration of ophthalmic diagnostic and treatment equipment; stay focused on unmet clinical needs; deepen industry-university-research-hospital collaborative innovation; and promote deep translation of frontier technologies into clinical applications.
11/
Ark Biopharma Presents Globally Innovative
Photodynamic Products at 19th IPA Congress
At the 19th Congress of the International Photodynamic Association (IPA), Qiming Venture Partners portfolio company Ark Biopharma (688176.SH) appeared under the theme "Illuminating the Future of Healing," presenting two globally innovative photodynamic diagnostic and therapeutic products. Among them, APL-1702 — the world's first and only non-invasive treatment for cervical precancerous lesions — has been validated through international multicenter Phase 3 clinical trials with confirmed efficacy, and is expected to provide a fertility-preserving, non-invasive solution for cervical cancer prevention in China and globally.
Ark Biopharma also exhibited APL-1706, an adjunct diagnostic and surgical drug for bladder cancer. This drug is currently the only approved imaging agent for bladder cancer diagnosis or surgery worldwide. The use of APL-1706 with blue light cystoscopy for non-muscle invasive bladder cancer (NMIBC) management has been incorporated into international and domestic guidelines and expert consensus.
Company Honors
5 Qiming Venture Partners Portfolio Companies Selected for BEYOND Awards
MedTech Beyond List and Great Health Navigation List
At the recently held BEYOND International Technology Innovation Expo (BEYOND Expo), the BEYOND Awards MedTech Beyond List and Great Health Navigation List were unveiled. The former aims to identify and recognize transformative forces in medtech that demonstrate exceptional innovation capabilities and achieve "defining industry top standards"; the latter focuses on leading enterprises that truly meet consumer health needs and demonstrate strong growth potential and outstanding innovation capabilities.
Qiming Venture Partners portfolio companies Dingke Medical, Wanzhongyixin, Xinsu Technology, and Insilico Medicine were selected for the BEYOND Awards MedTech Beyond List; Fushoukang was selected for the BEYOND Awards Great Health Navigation List.
Previous Issues
Qiming Weekly | Qiming Venture Partners Portfolio Company Financing and Updates Vol. 19, 2025 Qiming Stars | WeRide Partners Again with Renault Group to Provide Autonomous Shuttle Service for French Open
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns in their industries.
Many of Qiming Venture Partners' portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, and Biren Technology.